These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 19180099

  • 21. Delayed fingolimod-associated asystole.
    Espinosa PS, Berger JR.
    Mult Scler; 2011 Nov; 17(11):1387-9. PubMed ID: 21652609
    [Abstract] [Full Text] [Related]

  • 22. Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial.
    Laroni A, Brogi D, Morra VB, Guidi L, Pozzilli C, Comi G, Lugaresi A, Turrini R, Raimondi D, Uccelli A, Mancardi GL, EAP Investigators.
    BMC Neurol; 2014 Apr 01; 14():65. PubMed ID: 24690227
    [Abstract] [Full Text] [Related]

  • 23. ACS chemical neuroscience molecule spotlight on gilenya (fingolimod; FTY720).
    Hopkins CR.
    ACS Chem Neurosci; 2011 Mar 16; 2(3):116-7. PubMed ID: 22778861
    [No Abstract] [Full Text] [Related]

  • 24. Kaposi sarcoma in a patient with relapsing-remitting multiple sclerosis receiving fingolimod.
    Tully T, Barkley A, Silber E.
    Neurology; 2015 May 12; 84(19):1999-2001. PubMed ID: 25878178
    [No Abstract] [Full Text] [Related]

  • 25. [Clinical significance of the cardiovascular effects of fingolimod treatment in multiple sclerosis].
    Széplaki G, Merkely B.
    Ideggyogy Sz; 2012 Nov 30; 65(11-12):369-76. PubMed ID: 23289171
    [Abstract] [Full Text] [Related]

  • 26. Oral fingolimod for the treatment of patients with relapsing forms of multiple sclerosis.
    Singer B, Ross AP, Tobias K.
    Int J Clin Pract; 2011 Aug 30; 65(8):887-95. PubMed ID: 21679286
    [Abstract] [Full Text] [Related]

  • 27. [New disease-modifying and symptomatic therapies for multiple sclerosis].
    Weise G, Buttmann M.
    MMW Fortschr Med; 2012 Apr 19; 154(7):64-6. PubMed ID: 22558878
    [No Abstract] [Full Text] [Related]

  • 28. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach.
    Gasperini C, Ruggieri S.
    Drug Des Devel Ther; 2012 Apr 19; 6():175-86. PubMed ID: 22888218
    [Abstract] [Full Text] [Related]

  • 29. Multiple sclerosis in 2010: Advances in monitoring and treatment of multiple sclerosis.
    Filippi M.
    Nat Rev Neurol; 2011 Feb 19; 7(2):74-5. PubMed ID: 21297650
    [No Abstract] [Full Text] [Related]

  • 30. Oral fingolimod to treat multiple sclerosis: see your cardiologist first.
    Sato DK, Callegaro D.
    Arq Neuropsiquiatr; 2014 Sep 19; 72(9):651-2. PubMed ID: 25252227
    [No Abstract] [Full Text] [Related]

  • 31. [Disease modifying drugs in multiple sclerosis and pregnancy].
    Tur C, Tintoré M, Aguilera C.
    Med Clin (Barc); 2012 Sep 22; 139(7):316-8. PubMed ID: 22743277
    [No Abstract] [Full Text] [Related]

  • 32. Fingolimod is a potential novel therapy for multiple sclerosis.
    Aktas O, Küry P, Kieseier B, Hartung HP.
    Nat Rev Neurol; 2010 Jul 22; 6(7):373-82. PubMed ID: 20551946
    [Abstract] [Full Text] [Related]

  • 33. [Fingolimod treatment in multiple sclerosis].
    Tanaka M.
    Nihon Rinsho; 2014 Nov 22; 72(11):2010-4. PubMed ID: 25518386
    [Abstract] [Full Text] [Related]

  • 34. Fingolimod therapy for multiple sclerosis.
    Willis MA, Cohen JA.
    Semin Neurol; 2013 Feb 22; 33(1):37-44. PubMed ID: 23709211
    [Abstract] [Full Text] [Related]

  • 35. Fingolimod for multiple sclerosis.
    Drug Ther Bull; 2012 Feb 22; 50(2):18-20. PubMed ID: 22329953
    [Abstract] [Full Text] [Related]

  • 36. The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
    Fragoso YD, Arruda CC, Arruda WO, Brooks JB, Damasceno A, Damasceno CA, Finkelsztejn A, Finkelsztejn J, Gama PD, Giacomo MC, Gomes S, Goncalves MV, Matta AP, de Morais MM, Oliveira EM, Ribeiro Y, Sato HK, Tauil CB.
    Arq Neuropsiquiatr; 2014 Sep 22; 72(9):712-4. PubMed ID: 25252236
    [Abstract] [Full Text] [Related]

  • 37. Tumefactive multiple sclerosis and fingolimod.
    Lovera J, Villemarette-Pittman N.
    J Neurol Sci; 2014 Sep 15; 344(1-2):1-2. PubMed ID: 24993468
    [No Abstract] [Full Text] [Related]

  • 38. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
    Sørensen PS.
    J Neurol Sci; 2011 Dec 15; 311 Suppl 1():S29-34. PubMed ID: 22206763
    [Abstract] [Full Text] [Related]

  • 39. Gilenya safety update: cardiac and macula.
    Huggins A, Sergott RC.
    Curr Opin Ophthalmol; 2012 Nov 15; 23(6):457-9. PubMed ID: 23047163
    [No Abstract] [Full Text] [Related]

  • 40. Progressive multifocal leukoencephalopathy in a patient taking the MS pill Gilenya.
    Clin Infect Dis; 2013 Oct 15; 57(8):ii. PubMed ID: 24195115
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.